Objective—To compare antibody responses to
intranasal and SC Bordetella bronchiseptica vaccines
in seropositive dogs.
Design—Randomized controlled study.
Animals—40 young adult Beagles vaccinated against
Procedure—Dogs were randomly assigned to 1 of 4
groups (intranasal vaccine, SC vaccine, intranasal and
SC vaccines, no vaccine) and vaccinated on day 0.
Serum and salivary B bronchiseptica-reactive antibody
responses were measured on days 0 through 7,
10, 14, 21, and 28.
Results—Dogs that were vaccinated with the SC vaccine,
alone or in combination with the intranasal vaccine,
had a significant increase in serum concentration
of B bronchiseptica-reactive IgG beginning on day 5
and persisting through day 28. Dogs that were vaccinated
with the intranasal vaccine alone had a significant
increase in serum concentration of B bronchiseptica-
reactive IgG beginning on day 10 and persisting
through day 28, but serum IgG concentration in these
dogs was significantly less than concentration in dogs
that received the SC vaccine. Neither vaccine had a
demonstrable effect on salivary concentrations of B
bronchiseptica-reactive IgA or IgG. On day 10, all vaccinated
groups had significantly higher serum IgA concentrations
than did unvaccinated control dogs.
Conclusions and Clinical Relevance—Results suggest
that the SC B bronchiseptica vaccine may be
used to stimulate antibody responses in seropositive
dogs. There was no apparent benefit to administering
these vaccines simultaneously. Intranasal vaccines
may not be effective for booster vaccination of dogs
previously exposed to or immunized against B bronchiseptica.
Dogs should be vaccinated at least 5 days
prior to exposure to B bronchiseptica. (J Am Vet Med
Objective—To determine comparative efficacy of
vaccines administered IM and intranasally, used alone
or sequentially, to protect puppies from infection with
Bordetella bronchiseptica and determine whether
systemic or mucosal antibody response correlated
Design—Randomized controlled trial.
Animals—50 specific-pathogen-free Beagle puppies.
Procedure—In 2 replicates of 25 dogs each, 14-weekold
puppies that were vaccinated against canine distemper
virus and parvovirus were vaccinated against B bronchiseptica via intranasal, IM, intranasal-IM, or IMintranasal
administration or were unvaccinated controls.
Puppies were challenge exposed via aerosol administration
of B bronchiseptica 2 weeks after final vaccination.
Clinical variables and systemic and mucosal antibody
responses were monitored for 10 days after challenge
exposure. Puppies in replicate 1 were necropsied
for histologic and immunohistochemical studies.
Results—Control puppies that were seronegative
before challenge exposure developed paroxysmal
coughing, signs of depression, anorexia, and fever.
Vaccinated puppies (either vaccine) that were seronegative
before challenge exposure had fewer clinical signs.
Puppies that received both vaccines had the least
severe clinical signs and fewest lesions in the respiratory
tract. Vaccinated dogs had significantly higher concentrations
of B bronchiseptica-reactive antibodies in
serum saliva before and after challenge. Antibody concentrations
were negatively correlated with bacterial
growth in nasal cavity and pharyngeal samples after
Conclusions and Clinical Relevance—Parenterally
and intranasally administered vaccines containing B
bronchiseptica may provide substantial protection
from clinical signs of respiratory tract disease associated
with infection by this bacterium. Administration
of both types of vaccines in sequence afforded the
greatest degree of protection against disease. (J Am
Vet Med Assoc 2001;218:367–375)